

Round Table – The most pressing needs – proposal for the next concrete actions

Academia/No-profit perspective

1. EU Countries are far behind US and China with respect to open ATMP/AGTMP clinical trials. Innovation in ATMP means discover novelties (= filing IP) and then explore clinical applications (clinical trials). This process is costly and risky. How to fill the gap?
2. In the academic clinical context we are experiencing , at least in CAR T application, that access to commercially available products can not fulfill the clinical needs of patients. How to manage it? In US leading Institutions, access to commercial and academic products are similar.